Recruiting
Phase 1

Ruxolitinib Cream

Sponsor:

Incyte Corporation

Code:

NCT07049575

Conditions

Hidradenitis Suppurativa

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Ruxolitinib Cream

Study Details

Brief summary:

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Conditions

Hidradenitis Suppurativa

Study ID

NCT07049575

Start date

Nov 3, 2025

Status verified date

Aug, 2026

Completion date

Dec 9, 2026

Anticipated

Primary completion date

Dec 9, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of HS for at least 6 months before screening visit.
  • Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
  • Total estimated treatment BSA > 20% at screening and baseline.
  • Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
  • Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
  • Further inclusion criteria apply.

Exclusion Criteria:

  • Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator.
  • Laboratory values outside of the protocol-defined ranges.
  • Further exclusion criteria apply.

Study Design

Enrollment

24 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Ruxolitinib 1.5 % Cream

Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.

Interventions

Ruxolitinib Cream

Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Primary outcome measure

  • Number of participants with Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to 24 weeks ]
  • Number of participants with TEAEs leading to treatment interruption, discontinuation [ Time Frame: Up to 24 weeks ]

Central Contacts and Locations

Central contacts

Incyte Corporation Call Center (US)

1.855.463.3463medinfo@incyte.com

Incyte Corporation Call Center (ex-US)

+800 00027423eumedinfo@incyte.com

Locations

Saguaro Dermatology

Recruiting

Phoenix, Arizona, United States, 85008

Amicis Research Center Valencia

Recruiting

Northridge, California, United States, 91324

Children'S Hospital of Orange County

Recruiting

Orange, California, United States, 92868

Clinical Trials Research Institute

Recruiting

Thousand Oaks, California, United States, 91320

Clarity Dermatology

Recruiting

Castle Rock, Colorado, United States, 80109

International Clinical Research Tennessee Llc

Recruiting

Sanford, Florida, United States, 32771

Lenus Research Medical Group, Llc

Recruiting

Sweetwater, Florida, United States, 33172

Trueblue Clinical Research

Recruiting

Tampa, Florida, United States, 33609

Lane Dermatology and Dermatologic Surgery

Recruiting

Columbus, Georgia, United States, 31904

Options Research Group, Llc

Recruiting

West Lafayette, Indiana, United States, 47906

Equity Medical, Llc

Recruiting

Bowling Green, Kentucky, United States, 42104

Delricht Research

Recruiting

Baton Rouge, Louisiana, United States, 70809

Revival Research Institute, Llc Troy

Recruiting

Troy, Michigan, United States, 48084

Red River Research Partners

Recruiting

Bolivar, Missouri, United States, 65613

Dr Bobby Buka, Md Greenwich Village

Recruiting

New York, New York, United States, 10012-1354

Equity Medical, Llc

Recruiting

New York, New York, United States, 10019

Red River Research Partners

Recruiting

Fargo, North Dakota, United States, 58103

Unity Clinical Research

Recruiting

Oklahoma City, Oklahoma, United States, 73118

Paddington Testing Co Inc

Recruiting

Philadelphia, Pennsylvania, United States, 19103

More Information

Sponsor

Incyte Corporation

Last update posted

Aug 6, 2026

Last verified

Aug, 2026

Keywords

  • Hidradenitis suppurativa
  • skin disease
  • ruxolitinb cream

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2026-08-06.